Tag:
Medicare
Latest Headlines
Latest Headlines
Medicare to cover Edwards' Sapien heart valve
For medical device companies, gaining Medicare reimbursement for surgical procedures involving their implants can be a sort of financial holy grail. Edwards Lifesciences ($EW) has reached that point now that the Centers for Medicare & Medicaid Services has agreed to pay for surgery involving its Sapien transcatheter heart valve.
Lawmakers pressure CMS to get going on doc-disclosure rules
Two senators are pushing regulators to issue rules for complying with the doctor-disclosure provisions of healthcare reform.
Radiologists seek to halt imaging reimbursement cuts
It looks as if budget issues are continuing to curtail the wider use of CT and MRI scans for crucial cancer and other screenings, a cumulative effect of $6 billion in federal reimbursement reductions...
GAO report finds some hospitals paying more for devices
Findings from a new Government Accountability Office report are causing some members of Congress to push for greater transparency so hospitals pay a fair price for implantable medical devices (IMDs).
Gloom for the pharma industry, yes. Doom? No
AstraZeneca's ( $AZN ) layoffs announcement yesterday touched off more than its share of hand-wringing. It may be a straw-that-broke-the-camel's-back case; this shedding of 7,300 jobs follows a spate
Medicare to pay docs for Provenge infusion costs
Dendreon ( $DNDN ) got some welcome news from U.S. health officials: Medicare and Medicaid will now pay for the cost of infusing its prostate cancer therapy Provenge . Previously, the government health
Supercommittee's failure is pharma's gain, for now
The so-called supercommittee's stupendous failure may have Washington and Wall Street wringing their hands, but pharma may actually be better off. Drug stocks are down this morning--along with
CBO: Pay-to-delay ban could save $4.8B
The Congressional Budget Office has analyzed the proposed pay-to-delay ban, and its money-saving estimate comes in at almost $5 billion. According to CBO, the Preserve Access to Affordable Generic
New Medicare code could boost Krystexxa sales
Savient Pharmaceuticals ( $SVNT ) has announced a bureaucratic breakthrough that could help increase sales of its new gout drug Krystexxa . The Centers for Medicare and Medicaid Services gave Krystexxa
Medicare affirms rule expected to erode Epogen sales
As expected, Medicare has changed its kidney-care guidelines to remove a requirement that helped fuel sales of Amgen's ( $AMGN ) anemia drug Epogen . Kidney dialysis providers were previously told to
